The lung seems to be an important immunoreactive organ where irritation such as smoking may increase risk not only for inflammatory diseases, but also neutralizing antibodies to biologicals like interferon β and monoclonal antibodies such as natalizumab, he concluded. While smoking should not prohibit use of natalizumab, the percentage of patients developing antibodies, neutralizing the effect of the treatment, is not negligible, Dr Olsson commented to Medscape Medical News. Therefore patients should be advised about our findings. This comes on top of an increased risk for MS with smoking, and probably a worse disease course.
Posted on: Sun, 05 Oct 2014 06:27:12 +0000
Trending Topics
Recently Viewed Topics
© 2015